[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
1. von Schweinitz D, Faundez A, Teichmann B, Birnbaum T, Koch A, Hecker H, Glüer S, Fuchs J, Pietsch T: Hepatocyte growth-factor-scatter factor can stimulate post-operative tumor-cell proliferation in childhood hepatoblastoma. Int J Cancer; 2000 Jan 15;85(2):151-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocyte growth-factor-scatter factor can stimulate post-operative tumor-cell proliferation in childhood hepatoblastoma.
  • Rapid growth of residual tumor after partial hepatectomy has been observed during the period of liver regeneration in children with malignant embryonal hepatoblastoma.
  • Markedly increased serum levels of HGF-SF up to 15 ng/ml were found in 13/18 patients after liver resection and in 6/16 patients with regressive tumors after chemotherapy, in comparison with 15 patients with non-pre-treated hepatoblastoma and 20 healthy children of the same age group.
  • The hepatoblastoma cell lines HepT1, HepT3 and HUH6 reacted with significantly increased proliferation to rhHGF-SF in these concentrations (1-15 ng/ml).
  • Cultured hepatoblastoma cells ceased to proliferate at 20-50 ng/ml HGF-SF, and they underwent cell death at >/=100 ng/ml.
  • In contrast, the hepatocellular-carcinoma cell line HepG2 decreased growth under HGF-SF in a dose-dependent manner.
  • [MeSH-major] Hepatoblastoma / pathology. Hepatocyte Growth Factor / physiology. Liver Neoplasms / pathology
  • [MeSH-minor] Cell Division / physiology. Child, Preschool. Fibroblasts / secretion. Humans. Infant. Proto-Oncogene Proteins c-met / genetics. Proto-Oncogene Proteins c-met / metabolism. RNA, Messenger / metabolism. Tumor Cells, Cultured


2. Sakai M, Miyake H, Tashiro S, Okumura Y, Kido H: Inhibitory effect of FK506 and cyclosporine A on the growth and invasion of human liver cancer cells. J Med Invest; 2004 Feb;51(1-2):63-9
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibitory effect of FK506 and cyclosporine A on the growth and invasion of human liver cancer cells.
  • BACKGROUND: The prognosis of liver transplantation for liver cancer is determined by recurrence in the liver graft.
  • In this study, the effects of immunosuppressors, FK506 and cyclosporine A (CsA) on the migration of liver cancer cells were investigated.
  • METHODS: The effects of FK506 at concentrations of 1-100 ng/mL and CsA at 1-1000 ng/mL on the growth of poorly and well differentiated human hepatocellular carcinoma cell lines, HLE and HuH-7, respectively, were examined.
  • After treatment of these cells with FK506 and CsA, the growth of these cells, their cytotoxicities and invasion assay on the Matrigel basement membrane invasion chamber were evaluated.
  • FK506 at concentration of 1 ng/mL significantly inhibited the invasion of poorly differentiated HLE, but not well differentiated HuH-7, after treatment for 2-5 days in culture (p<0.05), but FK 506 at 10 ng/mL showed less inhibitory efficient.
  • CsA at concentrations of 1-10 ng/mL, however, did not inhibit or transiently inhibited the invasion of both cell lines.
  • The production of ICAM-1 in HLE and HuH-7 was suppressed by FK506 at concentrations of 1-10 ng/mL after treatment for 3-5 days but the effect was not significant in the initial phase at days 1-2 and the last phase at days 5-6.
  • [MeSH-major] Carcinoma, Hepatocellular / drug therapy. Cyclosporine / pharmacology. Liver Neoplasms / drug therapy. Tacrolimus / pharmacology
  • [MeSH-minor] Cell Division / drug effects. Cell Line, Tumor. Humans. Immunosuppressive Agents / pharmacology. Intercellular Adhesion Molecule-1 / biosynthesis. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15000258.001).
  • [ISSN] 1343-1420
  • [Journal-full-title] The journal of medical investigation : JMI
  • [ISO-abbreviation] J. Med. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 126547-89-5 / Intercellular Adhesion Molecule-1; 83HN0GTJ6D / Cyclosporine; WM0HAQ4WNM / Tacrolimus
  •  go-up   go-down


3. Warmann SW, Frank H, Heitmann H, Ruck P, Herberts T, Seitz G, Fuchs J: Bcl-2 gene silencing in pediatric epithelial liver tumors. J Surg Res; 2008 Jan;144(1):43-8
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bcl-2 gene silencing in pediatric epithelial liver tumors.
  • BACKGROUND: Proteins of the Bcl-2 family prevent cells of various tumor types from undergoing apoptosis and thus contribute to their chemotherapy resistance.
  • The phenotype of multidrug resistance is a major factor for poor treatment results of advanced epithelial liver tumors in children.
  • The purpose of this study was to analyze the influence of Bcl-2 on the chemotherapy resistance of hepatoblastoma (HB) and pediatric hepatocellular carcinoma (HCC).
  • MATERIALS AND METHODS: Bcl-2 expression was analyzed in the HB cell lines HUH6 and HepT1 as well as in the HCC cell line HepG2 before and after treatment with cisplatin, doxorubicin, taxol, and etoposid.
  • Treatment efficiencies of cytotoxic agents were assessed against original and Bcl-2 siRNA transfected tumor cells.
  • RESULTS: The mixed HB cell line HUH6 showed a relevant amount of Bcl-2 expression, which increased after chemotherapy.
  • Treatment with all cytotoxic agents was significantly improved through Bcl-2 siRNA (P < 0.001-0.0054) in this cell line.
  • Thus, this gene might serve as target for a gene-directed adjuvant therapy.
  • Further studies seem necessary to clear the susceptibility of pediatric epithelial liver tumors toward the described approach.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Drug Resistance, Neoplasm / genetics. Gene Silencing. Liver Neoplasms / genetics. Proto-Oncogene Proteins c-bcl-2 / genetics
  • [MeSH-minor] Antibiotics, Antineoplastic / pharmacology. Antineoplastic Agents, Phytogenic / pharmacology. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Apoptosis / drug effects. Apoptosis / physiology. Blotting, Western. Cell Line, Tumor. Child. Cisplatin / pharmacology. Doxorubicin / pharmacology. Drug Resistance, Multiple / genetics. Epithelium. Etoposide / pharmacology. Genetic Therapy / methods. Humans. Paclitaxel / pharmacology. Transfection

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17574594.001).
  • [ISSN] 0022-4804
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Proto-Oncogene Proteins c-bcl-2; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


Advertisement
4. Warmann S, Göhring G, Teichmann B, Geerlings H, Pietsch T, Fuchs J: P-glycoprotein modulation improves in vitro chemosensitivity in malignant pediatric liver tumors. Anticancer Res; 2003 Nov-Dec;23(6C):4607-11
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P-glycoprotein modulation improves in vitro chemosensitivity in malignant pediatric liver tumors.
  • BACKGROUND: Multidrug resistance (MDR) is a major reason for the poor outcome of advanced pediatric liver malignancies.
  • Our aim was to investigate the influence of P-gP antagonizers on the chemotherapy of pediatric liver malignancies in vitro.
  • MATERIALS AND METHODS: One hepatocellular carcinoma (HCC) and three hepatoblastoma (HB) cell lines were incubated with doxorubicin or cisplatin.
  • RESULTS: Modulation of P-gP improved chemotherapy results in all HB cell lines, more effectively in the more highly differentiated tumors.
  • Combined treatment of the HCC cell line was only more efficient using doxorubicin and PSC 833.
  • [MeSH-major] Acridines / therapeutic use. Antineoplastic Agents / therapeutic use. Cyclosporins / therapeutic use. Liver Neoplasms / drug therapy. P-Glycoprotein / antagonists & inhibitors. Tetrahydroisoquinolines / therapeutic use
  • [MeSH-minor] Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / pathology. Cell Survival / drug effects. Child. Cisplatin / therapeutic use. Doxorubicin / therapeutic use. Drug Resistance, Multiple / drug effects. Hepatoblastoma / drug therapy. Hepatoblastoma / pathology. Humans. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14981903.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Acridines; 0 / Antineoplastic Agents; 0 / Cyclosporins; 0 / P-Glycoprotein; 0 / Tetrahydroisoquinolines; 121584-18-7 / valspodar; 80168379AG / Doxorubicin; N488540F94 / Elacridar; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


5. Yu SB, Kim HY, Eo H, Won JK, Jung SE, Park KW, Kim WK: Clinical characteristics and prognosis of pediatric hepatocellular carcinoma. World J Surg; 2006 Jan;30(1):43-50
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and prognosis of pediatric hepatocellular carcinoma.
  • INTRODUCTION: Hepatocellular carcinoma (HCC) is a rare pediatric malignancy that is usually advanced at diagnosis, with a relatively poor prognosis.
  • Extensive treatment, including complete tumor resection, is believed to be necessary for cure.
  • This study was performed to analyze treatment results and to search for prognostic factors of pediatric HCC.
  • As a predisposing condition, hepatitis B virus (HBV) infections were present in 11 (68.8%) and liver cirrhosis in 8 (50.0%).
  • Including 1 patient with a liver transplant, 4 patients (25.0%) underwent a primary operation with complete tumor resection, and 11 (68.8%) received neoadjuvant chemotherapy because of their inoperable state at diagnosis.
  • After neoadjuvant chemotherapy, complete tumor resection was performed in four (36.4%).
  • CONCLUSIONS: This study confirmed that complete tumor resection is essential for cure in pediatric patients with HCC, and neoadjuvant chemotherapy improves the tumors' resectability.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Neoplasms / surgery
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Child, Preschool. Female. Humans. Infant. Male. Neoadjuvant Therapy. Neoplasm Staging. Prognosis. Radiography. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Surg. 1988 May;23(5):457-61 [2837562.001]
  • [Cites] J Gastroenterol Hepatol. 1999 Jun;14(6):594-9 [10385071.001]
  • [Cites] Med Pediatr Oncol. 2002 Nov;39(5):519-23 [12228910.001]
  • [Cites] J Pediatr Surg. 1998 Sep;33(9):1350-4 [9766351.001]
  • [Cites] Semin Pediatr Surg. 2000 Nov;9(4):196-208 [11112837.001]
  • [Cites] J Pediatr Surg. 2002 Feb;37(2):240-5 [11819207.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(6):1279-84 [10715298.001]
  • [Cites] J Cell Sci. 1991 Mar;98 ( Pt 3):317-22 [1676033.001]
  • [Cites] Cancer. 2003 Apr 15;97(8):2006-12 [12673731.001]
  • [Cites] World J Surg. 2001 Feb;25(2):126-30 [11338010.001]
  • [Cites] Pediatr Surg Int. 1997 Apr;12(4):266-70 [9099643.001]
  • [Cites] J Hepatol. 2001 Sep;35(3):421-30 [11592607.001]
  • [Cites] Int J Cancer. 1988 Oct 15;42(4):511-20 [3170025.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2798-804 [12065556.001]
  • [Cites] Ann Surg. 1999 Jul;230(1):1-8 [10400029.001]
  • [Cites] J Clin Oncol. 1991 Dec;9(12):2167-76 [1720452.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2789-97 [12065555.001]
  • [Cites] J Pediatr Surg. 1996 Jun;31(6):835-9 [8783117.001]
  • [Cites] Eur J Cancer. 2000 Jul;36(11):1418-25 [10899656.001]
  • [Cites] Vaccine. 2000 Feb 18;18 Suppl 1:S35-8 [10683542.001]
  • [Cites] Cancer. 1982 Sep 1;50(5):821-6 [6284345.001]
  • [Cites] Semin Pediatr Surg. 2001 Aug;10(3):140-5 [11481651.001]
  • (PMID = 16369702.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Iida T, Suenaga M, Takeuchi Y, Kobayashi T, Tobinaga J, Miwa T, Takenaka H, Nomura H, Hasegawa S, Oguma K: Successful resection of a ruptured hepatoblastoma prior to chemotherapy: report of a case. Surg Today; 2004;34(8):710-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful resection of a ruptured hepatoblastoma prior to chemotherapy: report of a case.
  • A 12-year-old boy was referred to our hospital suffering from severe anemia and liver dysfunction.
  • Abdominal ultrasonography revealed a mass measuring 51 x 49 mm in size, and abdominal computed tomography showed a low-density mass in S8 of Couinaud's segment and a low-density area in S7, thus suggesting bleeding in the tumor.
  • A diagnosis of pediatric liver carcinoma was made, and the case was classified as T2 C3 V0 N0 M0 Stage IIIA.
  • Although there was no evidence of bleeding during angiography, because of the high risk of rebleeding, a laparotomy was performed before chemotherapy.
  • The patient was transferred to the pediatric department and treated with six courses of intravenous chemotherapy followed by peripheral blood stem cell transplantation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hepatoblastoma / surgery. Liver Neoplasms / surgery
  • [MeSH-minor] Child. Hepatectomy. Humans. Liver / pathology. Male. Rupture

  • Genetic Alliance. consumer health - Hepatoblastoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15290405.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 18
  •  go-up   go-down


7. Seitz G, Krause R, Fuchs J, Heitmann H, Armeanu S, Ruck P, Warmann SW: In vitro photodynamic therapy in pediatric epithelial liver tumors promoted by hypericin. Oncol Rep; 2008 Nov;20(5):1277-82
Hazardous Substances Data Bank. PERYLENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro photodynamic therapy in pediatric epithelial liver tumors promoted by hypericin.
  • Limited treatment results in advanced pediatric liver tumors have emphasised the need for alternative treatment approaches in these malignancies.
  • Photodynamic therapy (PDT) has been proposed as promising treatment approach in various malignancies.
  • However, there exist no data on the effects of hypericin as photodynamic agent in pediatric malignant epithelial liver tumors.
  • In this study, we investigated the potential role of hypericin for visualization and treatment in hepatoblastoma (HB) and pediatric hepatocellular carcinoma (HCC) cells.
  • Two HB cell lines (HUH6, HepT1) and one HCC cell line (HepG2) were incubated with ascending concentrations of hypericin.
  • PDT with white light was performed for varying time intervals.
  • Cell viability, cell proliferation and apoptotic rates were assessed using MTT assay, Ki-67 immunocytochemisty and TUNEL test, respectively.
  • The changes within tumor cells under therapy were monitored using standard cytology.
  • Relevant hypericin uptake was observed in all cell lines according to the applied concentrations.
  • Histological analysis revealed no alterations of cell structure in HB and HCC cells after solely hypericin uptake, but severe alterations were found after PDT.
  • Enhancement of the hypericin concentration (up to 12.5 microM) and illumination time of up to 40 min resulted in a decrease of tumor cell viability (HUH6 99.8+/-2.4%, HepT1 99+/-2%, HepG2 98.4+/-1.6%, p<0.05), proliferative activity and complete apoptosis of all cells in all investigated cell lines.
  • These data show that hypericin might be a useful tool for visualisation and as alternative treatment option in HB and HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / drug therapy. Hepatoblastoma / drug therapy. Liver Neoplasms / drug therapy. Perylene / analogs & derivatives. Photochemotherapy / methods. Photosensitizing Agents / pharmacology
  • [MeSH-minor] Apoptosis / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Cell Survival / drug effects. Child. Flow Cytometry. Humans. In Situ Nick-End Labeling. In Vitro Techniques. Microscopy, Fluorescence

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18949433.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 5QD5427UN7 / Perylene; 7V2F1075HD / hypericin
  •  go-up   go-down


8. Harting MT, Blakely ML, Herzog CE, Lally KP, Ajani JA, Andrassy RJ: Treatment issues in pediatric gastric adenocarcinoma. J Pediatr Surg; 2004 Aug;39(8):e8-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment issues in pediatric gastric adenocarcinoma.
  • Modern treatment includes chemotherapy, radiotherapy, and surgery and has evolved over the past decade.
  • The case will be followed by a brief discussion of the presentation, current management guidelines, and prognosis of this rare pediatric entity.
  • [MeSH-major] Camptothecin / analogs & derivatives. Carcinoma, Signet Ring Cell / surgery. Stomach Neoplasms / surgery
  • [MeSH-minor] Anastomosis, Roux-en-Y. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Catheter Ablation. Chemotherapy, Adjuvant. Child. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Gastrectomy. Gastritis / complications. Helicobacter Infections / complications. Helicobacter pylori. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Lymph Node Excision. Neoplasm Recurrence, Local / surgery. Neoplastic Syndromes, Hereditary. Pancreatectomy. Prognosis. Radiation-Sensitizing Agents / administration & dosage. Radiotherapy, Adjuvant. Remission Induction. Reoperation. Splenectomy. Taxoids / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15300556.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiation-Sensitizing Agents; 0 / Taxoids; 15H5577CQD / docetaxel; 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


9. Czauderna P: Adult type vs. Childhood hepatocellular carcinoma--are they the same or different lesions? Biology, natural history, prognosis, and treatment. Med Pediatr Oncol; 2002 Nov;39(5):519-23
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult type vs. Childhood hepatocellular carcinoma--are they the same or different lesions? Biology, natural history, prognosis, and treatment.
  • BACKGROUND: Differences in the biology, natural history, and treatment results of hepatocellular carcinoma (HCC) in children and adults were sought based on the literature and experience resulting from SIOPEL 1 trial.
  • PROCEDURE: In the SIOPEL1 study, 40 children with HCC were registered from January 1990 to February 1994.
  • All, but two patients, received preoperative chemotherapy (PLADO--cisplatin and doxorubicin).
  • Outcome, response to treatment, and prognostic factors were analyzed using the SAS statistical package.
  • Partial response to chemotherapy was observed in 18 of 37 cases evaluated (49%).
  • A large number of "de novo" HCC cases, fairly high response rate to preoperative chemotherapy (49%) and 54% survival after complete resection constitute a significant difference in comparison with adult HCC series.
  • CONCLUSIONS: Survival for pediatric HCC patients is below 30%.
  • New multi-center prospective studies in children with HCC are required to better results and to allow further study of differences between adult and pediatric HCC should they exist.
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Liver Neoplasms / mortality
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Male. Poland. Prognosis. Survival Analysis. Treatment Outcome


10. Chen CJ, You SL, Lin LH, Hsu WL, Yang YW: Cancer epidemiology and control in Taiwan: a brief review. Jpn J Clin Oncol; 2002 Mar;32 Suppl:S66-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There has been a decreasing trend for cancers of the stomach and cervix uteri, while an increasing trend has been observed for cancers of the lung, liver, oral cavity, colon and rectum, breast and prostate.
  • International comparison and migrant studies have shown an elevated risk of hepatocellular carcinoma, nasopharyngeal carcinoma and cervical neoplasia in Taiwan.
  • The national hepatitis B vaccination program, started in July 1984, has resulted in a significant decrease in childhood hepatocellular carcinoma in Taiwan.
  • Project-based screening for hepatocellular carcinoma, nasopharyngeal carcinoma and breast cancer among high-risk groups was started in 1994.
  • Most cancer patients are diagnosed by pathological examinations and treated by surgical operation, chemotherapy and radiotherapy in major teaching hospitals in Taiwan.
  • The Taiwan Collaborative Oncology Group has been organized to assess the efficacy of various treatment modalities through multicentric clinical trials.
  • Major fields of the research include cancer genomics, gene therapy, molecular epidemiology and DNA vaccine.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11959880.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Japan
  • [Number-of-references] 52
  •  go-up   go-down


11. Kumagai H, Masuda T, Oikawa H, Endo K, Endo M, Takano T: Focal nodular hyperplasia of the liver: direct evidence of circulatory disturbances. J Gastroenterol Hepatol; 2000 Nov;15(11):1344-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Focal nodular hyperplasia of the liver: direct evidence of circulatory disturbances.
  • Focal nodular hyperplasia of the liver is a lesion characterized by a well-circumscribed region of hyperplastic liver parenchyma and contains a stellate fibrous scar.
  • The lesion is thought to be because of liver-cell hyperplasia that is caused by focal circulatory disturbances.
  • We describe here a pediatric case of this lesion that provided direct histopathologic evidence of circulatory disturbances.
  • Although there was no stellate scar present in our case, the presence of bile ductular proliferation at the periphery of the nodule was helpful in distinguishing this lesion from adenoma and hepatocellular carcinoma.
  • It is possible that such chemotherapy contributed to thrombosis in our case.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Female. Hepatic Artery. Humans. Infant. Liver / blood supply. Necrosis. Portal Vein. Thrombosis / complications. Thrombosis / diagnosis. Wilms Tumor / complications. Wilms Tumor / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Gastroenterol Hepatol. 2000 Nov;15(11):1229-31 [11129213.001]
  • (PMID = 11129233.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


12. Czauderna P, Popadiuk S, Korzon M, Stoba C, Szymik-Kantorowicz S, Sawicz-Birkowska K, Lopatka B, Bogusławska-Jaworska J, Kowalczyk J, Sopyło B, Madziara W, Juszkiewicz P, Swiatkiewicz V, Skotnicka-Klonowicz G, Włodarczyk A: Multicenter retrospective analysis of various primary pediatric malignant hepatic tumors--management in a series of 47 Polish patients (1985-1995). Eur J Pediatr Surg; 2001 Apr;11(2):82-5
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicenter retrospective analysis of various primary pediatric malignant hepatic tumors--management in a series of 47 Polish patients (1985-1995).
  • Forty-seven children treated in various Polish centers between 1985 and 1995 for primary malignant liver tumors were retrospectively analyzed.
  • In 44% of HB patients the tumor involved both liver lobes.
  • Chemotherapy was applied in 92% of cases (preoperatively in 67%).
  • Mean observation time was 58 months.
  • Involvement of both lobes of the liver and multifocality of the tumor were other adverse prognostic factors.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatoblastoma / surgery. Liver Neoplasms / surgery. Neoplasms, Germ Cell and Embryonal / surgery
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Poland / epidemiology. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11371041.001).
  • [ISSN] 0939-7248
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


13. Reingruber B, Boettcher MI, Klein P, Hohenberger W, Pelz JO: Hyperthermic intraperitoneal chemoperfusion is an option for treatment of peritoneal carcinomatosis in children. J Pediatr Surg; 2007 Sep;42(9):E17-21
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperthermic intraperitoneal chemoperfusion is an option for treatment of peritoneal carcinomatosis in children.
  • BACKGROUND: Gastrointestinal carcinomas in childhood are rare and frequently present at an advanced stage.
  • In addition to surgery and intravenous chemotherapy, hyperthermic intraperitoneal chemoperfusion (HIPEC) may be an option for selected patients.
  • METHODS: After treating a series of adult patients, HIPEC for peritoneal carcinomatosis from a signet cell carcinoma of the colon was performed intraoperatively in a 12-year-old boy.
  • We performed intraoperative drug level monitoring and daily postoperative liver and kidney function tests and differential blood counts.
  • Perfusate and venous drug levels were similar to those in an adult case.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Carcinoma, Signet Ring Cell / drug therapy. Carcinoma, Signet Ring Cell / secondary. Chemotherapy, Cancer, Regional Perfusion. Hyperthermia, Induced. Mitomycin / administration & dosage. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17848227.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


14. Shorter NA, Glick RD, Klimstra DS, Brennan MF, Laquaglia MP: Malignant pancreatic tumors in childhood and adolescence: The Memorial Sloan-Kettering experience, 1967 to present. J Pediatr Surg; 2002 Jun;37(6):887-92
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant pancreatic tumors in childhood and adolescence: The Memorial Sloan-Kettering experience, 1967 to present.
  • BACKGROUND: Malignant tumors of the pancreas are uncommon in children and adolescents and only recently have the most common tumor types been well characterized.
  • As a result, the treatment approach to these patients has yet to be standardized, and much of the information available in the literature, particularly with regard to the role of chemotherapy and radiation, is anecdotal.
  • The pathologic types were pancreatoblastoma, 5; solid pseudopapillary tumor, 7; acinar cell carcinoma, 1; nonfunctioning pancreatic endocrine neoplasm, 1; malignant VIPoma, 1; and PNET, 2.
  • Chemotherapy or radiation were used in selected cases.
  • The roles of chemotherapy and radiation remain undefined.
  • [MeSH-major] Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Carcinoma, Acinar Cell / pathology. Carcinoma, Acinar Cell / therapy. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Male. Neoplasm Recurrence, Local. Pancreatectomy. Radiotherapy, Adjuvant. Retrospective Studies. Risk Assessment. Treatment Outcome. Vipoma / pathology. Vipoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002, Elsevier Science (USA). All rights reserved.
  • (PMID = 12037756.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. De Backer A, Madern GC, Oosterhuis JW, Hakvoort-Cammel FG, Hazebroek FW: Ovarian germ cell tumors in children: a clinical study of 66 patients. Pediatr Blood Cancer; 2006 Apr;46(4):459-64
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian germ cell tumors in children: a clinical study of 66 patients.
  • BACKGROUND: Ovarian germ cell tumors are rare in childhood.
  • The aim of this study is to review clinical presentation, management, and outcome in a two-center series of girls with ovarian germ cell tumor.
  • PROCEDURE: The records of 66 patients (median age 9 years) with histologically proven ovarian germ cell tumor (either benign or malignant), treated over a 44-year-span, were reviewed.
  • Most patients (52) were stage I, 4 were stage II, 6 stage III, and 1, with liver metastases, stage IV.
  • Unilateral salpingo-oophorectomy was the most frequently performed procedure (n = 46), and ovarian-sparing tumorectomy was performed in 9 patients (one bilaterally).
  • Histologically, teratomas were found most frequently (mature: 45, immature: 9), followed by mixed tumors (n = 7), yolk sac tumors (n = 3), dysgerminoma (n = 2), gonadoblastoma (n = 2), and embryonal carcinoma (n = 1).
  • Surgical removal of the tumor with or without the ovary and/or adnex was the sole treatment in 55 patients, chemotherapy was administered in 10 and radiotherapy + chemotherapy in one.
  • The 64 survivors are now between 8 months and 44 years after treatment.
  • CONCLUSIONS: With a recurrence rate of 4.5% and a mortality rate of 3%, this series confirms the excellent prognosis for girls with ovarian germ cell tumor (GCT).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Germ Cell and Embryonal / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Magnetic Resonance Imaging. Neoplasm Staging. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16206211.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


16. Mingo L, Seguel F, Rollán V: Intraabdominal desmoplastic small round cell tumour. Pediatr Surg Int; 2005 Apr;21(4):279-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraabdominal desmoplastic small round cell tumour.
  • Desmoplastic small round cell tumour (DSRCT) is an extremely rare neoplasm.
  • Laboratory values were altered, and imaging showed multiples masses in the liver and retroperitoneum.
  • He was treated with chemotherapy but died of hepatic failure.
  • After treatment with chemotherapy, two operations were carried out to resect different intraabdominal masses.
  • The first patient died due to the advanced stage of the disease, and the second died after chemotherapy, peripheral blood stem transplantation, and multiple operations.
  • The occurrence of this type of tumour in the paediatric age group as well as its high malignancy is noteworthy.
  • Until more effective forms of treatment are found, we recommend treatment with chemotherapy, surgery, and radiotherapy, with close monitoring of the patient.
  • [MeSH-major] Abdominal Neoplasms / surgery. Carcinoma, Small Cell / surgery
  • [MeSH-minor] Child. Child, Preschool. Fatal Outcome. Humans. Inguinal Canal. Liver Neoplasms / diagnostic imaging. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1998 Nov;22(11):1303-13 [9808123.001]
  • [Cites] Cancer. 1996 Aug 15;78(4):845-51 [8756380.001]
  • [Cites] Eur J Pediatr Surg. 2002 Oct;12(5):333-6 [12469262.001]
  • [Cites] J Surg Oncol. 1999 Aug;71(4):269-72 [10440769.001]
  • [Cites] J Pediatr Hematol Oncol. 2000 Sep-Oct;22(5):446-50 [11037858.001]
  • [Cites] Pediatr Hematol Oncol. 1996 Jan-Feb;13(1):95-9 [8718507.001]
  • [Cites] Ann Surg Oncol. 1998 Jul-Aug;5(5):416-22 [9718171.001]
  • [Cites] Pediatr Pathol. 1989;9(2):177-83 [2473463.001]
  • [Cites] Surg Oncol. 2000 Aug;9(2):77-81 [11094327.001]
  • (PMID = 15761710.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


17. Imataki O, Makimoto A, Kojima R, Sakiyama M, Hosono A, Takaue Y: Intensive multimodality therapy including paclitaxel and reduced-intensity allogeneic hematopoietic stem cell transplantation in the treatment of adrenal cancer with multiple metastases. Int J Clin Oncol; 2006 Apr;11(2):156-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive multimodality therapy including paclitaxel and reduced-intensity allogeneic hematopoietic stem cell transplantation in the treatment of adrenal cancer with multiple metastases.
  • Adrenocortical carcinoma is a rare malignancy in adolescents and young adults.
  • The prognosis of unresectable/metastatic adrenocortical carcinoma remains very poor because the rarity of the tumor has made it difficult to establish treatment guidelines, and diagnosis and the resultant treatment can be greatly delayed.
  • We treated a 24-year-old woman who was diagnosed with adrenocortical carcinoma of the right adrenal gland which extended to the inferior vena cava.
  • Although she underwent surgical resection of the extensive tumor as the primary treatment, the disease recurred in the lung and liver as multiple metastases shortly after surgery.
  • She received intensive multimodality therapy, including chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP regimen), embolization of the feeding arteries, and proton irradiation for the liver mass.
  • Finally, she underwent reduced-intensity allogeneic hematopoietic stem cell transplantation from an HLA 1-locus-mismatched sibling donor.
  • Although this experience is limited, we suggest that TIP chemotherapy was effective for adrenocortical carcinoma, and a graft-versus-tumor effect after reduced-intensity stem cell transplantation may have contributed to the prolonged survival.
  • [MeSH-major] Adrenal Gland Neoplasms / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Liver Neoplasms / therapy. Lung Neoplasms / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Fatal Outcome. Female. Graft vs Host Disease. Humans


18. Reinhard H, Aliani S, Ruebe C, Stöckle M, Leuschner I, Graf N: Wilms' tumor in adults: results of the Society of Pediatric Oncology (SIOP) 93-01/Society for Pediatric Oncology and Hematology (GPOH) Study. J Clin Oncol; 2004 Nov 15;22(22):4500-6
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wilms' tumor in adults: results of the Society of Pediatric Oncology (SIOP) 93-01/Society for Pediatric Oncology and Hematology (GPOH) Study.
  • PURPOSE: In the Society of Pediatric Oncology (SIOP) 93-01 study, 30 patients older than 16 years were found to have Wilms' tumor.
  • They were treated according to the pediatric protocol and were analyzed for clinical presentation, stage distribution, and prognosis.
  • Tumor stages were defined according to SIOP, and treatment was risk-adapted according to SIOP 93-01/Society for Pediatric Oncology and Hematology (GPOH) protocol.
  • RESULTS: Ten patients (33%) had metastatic disease at the time of diagnosis (liver, four patients; lung, three patients; liver and lung, three patients).
  • Histologic studies revealed intermediate-risk in 23 of 30 tumors; two tumors were classified as high-risk; and three tumors were clear-cell sarcomas.
  • Two of 30 patients showed a nephroblastoma and a renal cell carcinoma simultaneously in the same kidney.
  • A complete remission was achieved in 24 patients; four patients relapsed after complete remission; and three of them reached a second remission with further treatment.
  • Event-free survival was 57%, with an overall survival of 83% (median observation time, 4 years).
  • CONCLUSION: Adults can be cured in a high percentage by a multimodal treatment according to pediatric protocols.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Kidney Neoplasms / drug therapy. Kidney Neoplasms / pathology. Wilms Tumor / drug therapy. Wilms Tumor / pathology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15542800.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


19. Nara M, Toyoki Y, Hakamada K, Narumi S, Ishido K, Sugai M, Munakata H, Ito E, Sasaki M: Living donor liver transplantation for a child with recurrent pediatric adult-type hepatocellular carcinoma. Transplant Proc; 2008 Oct;40(8):2828-9
MedlinePlus Health Information. consumer health - Organ Donation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Living donor liver transplantation for a child with recurrent pediatric adult-type hepatocellular carcinoma.
  • INTRODUCTION: Pediatric hepatocellular carcinoma (HCC) is an uncommon disease with a poor prognosis.
  • There are few reports about liver transplantation for pediatric adult-type HCC.
  • We experienced a case of living donor liver transplantation (LDLT) for a child with recurrent pediatric adult-type HCC.
  • He underwent hepatectomy after 3 courses of chemotherapy in July 2005.
  • After the operation, he had 2 more courses of the same chemotherapy.
  • However, his alpha-fetoprotein level increased and a computed tomography (CT) scan showed recurrent tumor in his remnant liver in October 2006.
  • He underwent another chemotherapy session immediately.
  • However, CT revealed multiple liver tumors after chemotherapy in December 2006.
  • CONCLUSION: Liver transplantation in conjunction with chemotherapy may have an increasing role in the management of pediatric HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Neoplasms / surgery. Living Donors
  • [MeSH-minor] Adult. Child. Female. Hepatectomy. Humans. Male. Neoplasm Recurrence, Local. Treatment Outcome. alpha-Fetoproteins / metabolism


20. Kinoshita Y, Tajiri T, Souzaki R, Tatsuta K, Higashi M, Izaki T, Takahashi Y, Taguchi T: Diagnostic value of lectin reactive alpha-fetoprotein for neoinfantile hepatic tumors and malignant germ cell tumors: preliminary study. J Pediatr Hematol Oncol; 2008 Jun;30(6):447-50
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of lectin reactive alpha-fetoprotein for neoinfantile hepatic tumors and malignant germ cell tumors: preliminary study.
  • BACKGROUND AND PURPOSE: The serum alpha-fetoprotein (AFP) level has been used as a tumor marker for hepatoblastoma, and malignant germ cell tumors in pediatric patients.
  • The AFP has 3 isoforms (L1, L2, L3), and the usefulness of the L3 fraction as a diagnostic marker for the adult hepatocellular carcinoma is well known.
  • However, there are few reports dealing with various pediatric malignant tumors.
  • In the current study, we analyzed the diagnostic value of AFP fractions for pediatric diseases, in particular, those occurring in the neoinfantile period.
  • MATERIALS AND METHODS: From 2003 to 2006, two cases of hepatoblastoma, and 5 cases of germ cell tumor, all of which were neoinfantile, were treated in our department.
  • RESULTS: In all cases of hepatoblastoma and yolk sac tumor, both the total AFP and the L3 fraction were high, either before treatment or in the presence of malignant tumors.
  • Most of the cases of neonatal immature teratoma showed a high total AFP level during the neoinfantile period, however, the L3 fraction was around 10%, and decreased after surgical treatment.
  • As the total AFP and the AFP-L3 fraction were proportionally elevated, the patient was treated with additional surgical resection and chemotherapy.
  • DISCUSSION: Our results indicated that the level of the L3 fraction accurately confirmed the existence, or the malignant potential of hepatic tumor or germ cell tumor.
  • [MeSH-major] Biomarkers, Tumor / blood. Hepatoblastoma / blood. Liver Neoplasms / blood. Neoplasms, Germ Cell and Embryonal / blood. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18525461.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Lectins; 0 / Protein Isoforms; 0 / alpha-Fetoproteins
  •  go-up   go-down


21. Lai MW, Yeh CT: The oncogenic potential of hepatitis B virus rtA181T/ surface truncation mutant. Antivir Ther; 2008;13(7):875-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The rtA181T mutant also conferred drug resistance to adefovir.
  • We discovered a 39-year-old patient with advanced hepatocellular carcionoma, who was seropositive for HBV e antigen but seronegative for HBV surface antigen.
  • Nucleotide sequence analysis revealed the presence of polymerase rtA1 81T/surface truncation mutant in both the serum and hepatoma samples.
  • Surprisingly, this patient has never received lamivudine or adefovir antiviral therapy.
  • CONCLUSION: Our data indicate that an HBV polymerase rtA181T/surface truncation mutant could emerge spontaneously without previous antiviral treatment.
  • The presence of this mutant in a patient with advanced hepatocellular carcinoma as well as its oncogenic potential warrants careful re-evaluation of the current strategy of prolonged antiviral therapy.
  • [MeSH-minor] Adult. Animals. Antiviral Agents / pharmacology. Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / virology. Cell Line, Tumor. Drug Resistance, Viral / genetics. Hepatitis B Surface Antigens / genetics. Hepatitis B e Antigens / blood. Humans. Lamivudine / pharmacology. Liver Neoplasms / pathology. Liver Neoplasms / virology. Liver Neoplasms, Experimental / pathology. Liver Neoplasms, Experimental / virology. Male. Mice. Mice, Inbred BALB C. Mice, Nude. NIH 3T3 Cells. Taiwan. Transcriptional Activation

  • Genetic Alliance. consumer health - Hepatitis.
  • Hazardous Substances Data Bank. LAMIVUDINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19043921.001).
  • [ISSN] 1359-6535
  • [Journal-full-title] Antiviral therapy
  • [ISO-abbreviation] Antivir. Ther. (Lond.)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Hepatitis B Surface Antigens; 0 / Hepatitis B e Antigens; 2T8Q726O95 / Lamivudine
  •  go-up   go-down


22. Tröbs RB, Hänsel M, Friedrich T, Bennek J: A 23-year experience with malignant renal tumors in infancy and childhood. Eur J Pediatr Surg; 2001 Apr;11(2):92-8
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A 23-year experience with malignant renal tumors in infancy and childhood.
  • A retrospective analysis of 77 children treated between 1974 and 1996 was undertaken to evaluate morbidity and the evolution of therapy.
  • High-risk WT were diagnosed in 12 of 63 patients (19%) (NB with anaplasia 10, clear cell sarcoma 1, malignant rhabdoid tumor 1).
  • We observed 3 children of school age with renal carcinoma and one patient with an intrarenal neuroblastoma.
  • According to the SIOP/GPOH protocol in 1989, the regimen was switched from primary surgery to preoperative chemotherapy without biopsy in 1989 (11 pats.).
  • During preoperative chemotherapy a venous occlusive disease of the liver occurred in 2 patients.
  • Preoperative chemotherapy led to an impressive tumor shrinkage in the majority of patients.
  • In our experience, reduction of tumor volume due to preoperative chemotherapy facilitates tumor removal by surgery and may prevent tumor spillage and the deleterious effects of radiation in young children.
  • Surgery without delay is necessary if the diagnosis is unclear or the tumor fails to respond to preoperative chemotherapy.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Male. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11371043.001).
  • [ISSN] 0939-7248
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down






Advertisement